A study found that sonodynamic therapy showed no adverse events and demonstrated cancer cell death in 3 patients with ...

Satoru Osuka, M.D., Ph.D., assistant professor in the University of Alabama at Birmingham Department of Neurosurgery, has been awarded a $50,000 seed grant from the Uncle Kory Foundation to support ...

Reoperation in recurrent glioblastoma patients may improve progression-free and overall survival, especially when tumors are in non-eloquent, accessible brain regions. Factors like age, gender, tumor ...

Glioblastoma is the most aggressive and most common malignant brain cancer in adults. It is currently treated with surgery, ...

The market for PDTs in oncology is projected to experience substantial growth in the coming years. This growth is driven by a rising number of patien ...

Window of opportunity trial reveals mechanisms of response and resistance to navtemadlin in patients with recurrent ...

Detailed price information for Cns Pharmaceuticals Inc (CNSP-Q) from The Globe and Mail including charting and trades.

Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system ...

TPI 287 has been well tolerated in over 350 patients to date, including in clinical trials as a monotherapy and in combination with bevacizumab for the treatment of recurrent glioblastoma ...

On-demand video webcast now available here HOUSTON, TX / ACCESSWIRE / 19, 2025 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ('CNS' or the 'Company'), a bi ...